Cancer Research and Treatment10.4143/crt.2021.2052022542469-477Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast CancerHyehyun Jeong, Jae Ho Jeong, Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Sung-Bae Kim,,
Annals of Oncology10.1016/j.annonc.2021.03.133202132S72-S73119P Clinical efficacy of everolimus and CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer by treatment sequenceJ.H. Jeong, H. Jeong, J.E. Kim, J-H. Ahn, K.H. Jung, S-B. Kim,
Drug Design, Development and Therapy10.2147/dddt.s3567572022Volume 16727-735Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant SettingHikmat Abdel-Razeq, Baha' Sharaf,
Value in Health10.1016/j.jval.2013.08.4212013167A396Comparison Between Everolimus (Afinitor®) and Chemotherapy Agents (Capecitabine, Docetaxel and Doxorubicin) for the Treatment of Hormone Receptor Positive (HR+) HER2 Negative (HER2–) Advanced or Metastatic Breast CancerJ. Vieira, D. Chandiwana, M. Taylor, L. Lewis,
Value in Health10.1016/j.jval.2013.08.4092013167A393-A394An Indirect Treatment Comparison of the Efficacy of Everolimus (Afinitor®) and Fulvestrant for the Treatment of Hormone Receptor Positive (HR+) HER2 Negative (HER2–) Advanced or Metastatic Breast CancerD. Chandiwana, J. Vieira, J. Granville, R. McCool, K. Fleetwood,
Breast Cancer Research10.1186/s13058-021-01394-y2021231Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapyMariya Rozenblit, Sophia Mun, Pamela Soulos, Kerin Adelson, Lajos Pusztai, Sarah Mougalian,,
Breast Cancer and Surgery10.5772/intechopen.765782018Adjuvant Systemic Treatment in Hormone Receptor Positive, HER2 Negative Breast CancerFatma Sen
Asia-Pacific Journal of Clinical Oncology10.1111/ajco.130642018143-11Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigmFrances Boyle, Jane Beith, Katie Burslem, Richard de Boer, Rina Hui, Elgene Lim, Nicole McCarthy, Andrew Redfern, Natasha Woodward,
OncoTargets and Therapy10.2147/ott.s2987202021Volume 142929-2939Advances in Therapy for Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer Patients Who Have Experienced Progression After Treatment with CDK4/6 InhibitorsChao Li, Xujun Li,
ESMO Open10.1016/j.esmoop.2020.100014202161100014ESMO20 YO for YO: highlights on adjuvant CDK4/6 inhibitors in early hormone receptor-positive/HER2-negative breast cancerA. Matikas, M. Lambertini,